deltatrials
Recruiting PHASE1 INTERVENTIONAL 3-arm NCT06946927

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

A Phase Ib, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of JMKX001899 in Combination With Other Therapies in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation.

Sponsor: Jemincare

Conditions NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions Carboplatin Chemotherapy: Pemetrexed IN10018 JMKX001899
Updated 3 times since 2025 Last updated: Jun 26, 2025 Started: Jun 6, 2025 Primary completion: Feb 28, 2026 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on NSCLC (Advanced Non-small Cell Lung Cancer), this trial is actively recruiting participants. The trial is conducted by Jemincare and has accumulated 3 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2025 – ~Aug 2025 · 3 months · monthly snapshotNot Yet Recruiting~Aug 2025 – present · 8 months · monthly snapshotRecruiting~Jan 2026 – present · 3 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE1

  2. Aug 2025 — Present [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  3. May 2025 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jemincare
Data source: Jemincare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations